In Vitro Organoid Drug Sensitivity-Guided Treatment for Advanced Pancreatic Neuroendocrine Tumor

Launched by RUIJIN HOSPITAL · Jan 30, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring a new way to treat advanced pancreatic neuroendocrine tumors, which are a type of cancer that can be difficult to treat. Researchers want to see if using a special test, called an organoid drug sensitivity test, can help doctors choose the best chemotherapy or targeted therapies for patients. The idea is to take a sample of the tumor from the patient, grow it in the lab, and see how it reacts to different treatments. This could lead to better treatment outcomes for patients who cannot have surgery or whose cancer has spread.

To participate in this trial, patients need to be between 18 and 75 years old and have a confirmed diagnosis of locally advanced or metastatic pancreatic neuroendocrine tumor. They should also be able to provide a fresh sample of their tumor for testing. Participants will undergo the organoid drug sensitivity test, and their treatment will be guided by the results. The study is currently recruiting participants, and those who join can expect close follow-up and care throughout the process. It’s important to note that individuals with other serious health issues or recent significant heart problems may not be eligible to participate.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥ 18 and ≤ 75 years old.
• • 2. Histologically or cytologically confirmed locally advanced/metastatic Pancreatic Neuroendocrine Tumor
• • 3. Surgery was considered impossible or can not receive the radical purpose.
• • 4. Able to provide fresh tumor tissue specimens for organoid culture, including: tumor biopsy tissues, tumor surgical specimens, etcy.
• • 5. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0-2.
• • 6. Expected survival time≥ six months.
• • 7. Patient have been informed and consented, compliance and geographic proximity to ensure adequate follow-up
• Exclusion Criteria:
• • 1. Other malignancies in the past 5 years, excluding cured basal cell carcinoma of the skin.
• • 2. History of severe cardiovascular events and myocardial Infarction within twelve months before the study.
• • 3. Patients with psychiatric disorders or with psychotropic substance abuse and inability to abstain.
• • 4. Pregnant or breastfeeding women.
• • 5. According to researcher's consideration, patients with other serious systemic diseases or other conditions that are not suitable for participation.